Clinical and Experimental Vaccine Research最新文献_第10页

Factors associated with side effects of COVID-19 vaccine in Indonesia 印度尼西亚与COVID-19疫苗副作用相关的因素

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.89

J. Wibowo, R. Heriyanto, F. Wijovi, D. A. Halim, C. Claudia, E. Marcella, B. Susanto, Michele Indrawan, Nadia Khoirunnisa Heryadi, Michelle Imanuelly, Jonathan Juniard Anurantha, T. Hariyanto, C.P.G.P.P. Marcellin, Terry Devita Sinaga, Saraswati Anindita Rizki, N. Sieto, J. Siregar, N. Lugito, A. Kurniawan

{"title":"Factors associated with side effects of COVID-19 vaccine in Indonesia","authors":"J. Wibowo, R. Heriyanto, F. Wijovi, D. A. Halim, C. Claudia, E. Marcella, B. Susanto, Michele Indrawan, Nadia Khoirunnisa Heryadi, Michelle Imanuelly, Jonathan Juniard Anurantha, T. Hariyanto, C.P.G.P.P. Marcellin, Terry Devita Sinaga, Saraswati Anindita Rizki, N. Sieto, J. Siregar, N. Lugito, A. Kurniawan","doi":"10.7774/cevr.2022.11.1.89","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.89","url":null,"abstract":"Purpose As coronavirus disease 2019 (COVID-19) continues to spread rapidly causing approximately 186 million confirmed cases around the world, the urgency to reach herd immunity through vaccination is increasing. However, vaccine safety is a top priority to limit the occurrence of adverse events. Henceforth, this study aims to recognize and perceive COVID-19 vaccine safety in Indonesia during the pandemic. Materials and Methods This is a cross-sectional study and was conducted in Indonesia during the COVID-19 pandemic using an online survey of demographic information and a qualitative questionnaire. Responses were recorded and the association between demographic characteristics from survey questions was tested using chi-square with a risk estimate and 95% confidence interval. Results A total of 311 participants from 33 out of 34 provinces in Indonesia participated in this study. Recorded responses showed multiple side effects of the COVID-19 vaccine both short- and long-term experienced by the participants. Significant associations were found between demographic factors and COVID-19 vaccine side effects such as female gender with short-term puncture site (odds ratio [OR], 0.463; 95% confidence interval [CI], 0.263–0.816) and short-term other reactions (OR, 0.463; 95% CI, 0.263–0.816), domicile outside Java island with long-term puncture site (OR, 4.219; 95% CI, 1.401–12.701) and immune reactions (OR, 3.375; 95% CI, 1.356–8.398), also between married marital status and long-term vagal reaction (OR, 4.655; 95% CI, 1.321–16.409). Conclusion Gender, domicile and marital status factors were associated with COVID-19 vaccine side effects in Indonesian people.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"89 - 95"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46645747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Successful seroconversion against diphtheria and tetanus induced through maternal vaccination in a region of Colombia 哥伦比亚某地区通过母体疫苗接种成功实现白喉和破伤风血清转换

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.72

D. Hincapié-Palacio, Adriana Echeverri, Cristina Hoyos, Felipe Vargas-Restrepo, Marta Ospina, Seti Buitrago, J. Ochoa

{"title":"Successful seroconversion against diphtheria and tetanus induced through maternal vaccination in a region of Colombia","authors":"D. Hincapié-Palacio, Adriana Echeverri, Cristina Hoyos, Felipe Vargas-Restrepo, Marta Ospina, Seti Buitrago, J. Ochoa","doi":"10.7774/cevr.2022.11.1.72","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.72","url":null,"abstract":"Purpose This study aims to compare protection against diphtheria and tetanus conferred on the mother and the neonate before and after maternal vaccination against tetanus, diphtheria, and acellular pertussis (Tdap), transfer of antibodies, and the variables that could impact on the protection. Materials and Methods The study followed a cohort of 200 pregnant women from a region in Colombia, contacted during prenatal control before vaccination and upon delivery. The work determined immunoglobulin G antibodies against diphtheria and tetanus of pregnant women and umbilical cord. The proportion of protection, the geometric mean of the concentration, and the transfer of maternal antibodies were calculated. The protection profile of the pregnant women was explored by using multiple correspondence analysis. Results The concentration of antibodies against diphtheria was significant before and after vaccination of the pregnant women (p=0.000) with proportions of 85.0% and 97.5%, respectively, and of 98.6% in the umbilical cord, with significant antibody correlation (Spearman’s coefficient=0.668, p=0.01). Sero-protection against tetanus before vaccination was at 71.0%, after at 92.6%, and in the umbilical cord at 95.9%, with significant antibody concentration before and after vaccination (p=0.000) and antibody correlation (Spearman’s coefficient=0.936, p=0.01). Sero-protection was higher when the pregnant women were vaccine 8 to 11 weeks before delivery. Unprotected pregnant women were those not vaccinated during pregnancy. Conclusion The high proportion of protection against diphtheria and tetanus and the placental transfer support the need to promote maternal immunization with Tdap.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"72 - 81"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42673636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia 与印度尼西亚乙型肝炎（Bio-Farma）疫苗相比，不同批量来源的重组乙型肝炎疫苗的保护性和安全性

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.43

Yetty M Nency, F. A. Rahmadi, Mulyono, D. T. Anantyo, Nurain Farhanah, Rebriarina Hapsari, H. Farida, U. Sadhana, Herry Djagat, T. Kristina, A. Juniarto, Mita Puspita, Rini Mulia Sari, N. Bachtiar

{"title":"Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia","authors":"Yetty M Nency, F. A. Rahmadi, Mulyono, D. T. Anantyo, Nurain Farhanah, Rebriarina Hapsari, H. Farida, U. Sadhana, Herry Djagat, T. Kristina, A. Juniarto, Mita Puspita, Rini Mulia Sari, N. Bachtiar","doi":"10.7774/cevr.2022.11.1.43","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.43","url":null,"abstract":"Purpose Indonesia, a high populous and the second-highest country in epidemicity of hepatitis B in South-East Asia require maintaining its capacity of monovalent hepatitis B production to keep up with both the national immunization program and global needs. To keep the sustainability of the vaccine, a new bulk is needed to be made available. This study aims to evaluate the immunogenicity and safety of Bio Farma newly formulated recombinant hepatitis B vaccines, which came from different sources of bulk, compared to the already registered hepatitis B vaccine. Materials and Methods An experimental, randomized, double-blind, cohort intervention phase II clinical trial was conducted on three recombinant hepatitis B vaccines from different bulk sources, with Bio Farma registered hepatitis B vaccine as the control group. A total of 536 participants around age 10 to 40 years old were thricely vaccinated with twice serological assessments. The subject’s safety was monitored for 28 days after each vaccination. Results Of 536 enrolled participants, 521 finished the vaccination and serology assessments. The investigational products were proven not to be inferior to the control. All vaccines were well tolerated. No differences in rates of local and systemic reactions were seen between the investigational products and control. No serious adverse event was found to be related to the investigational vaccines. Conclusion Investigational vaccines are shown to be equally immunogenic and safe as the control vaccine.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"43 - 52"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42723223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels 骆驼产气荚膜梭状芽孢杆菌和牛病毒性腹泻联合疫苗的制备及现场研究

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.30

H. Elhelw, Maha Raafat Abd el Fadeel, E. El-Sergany, A. Allam, M. K. Elbayoumy, A. El-Kattan, A. A. El-Kholy

{"title":"Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels","authors":"H. Elhelw, Maha Raafat Abd el Fadeel, E. El-Sergany, A. Allam, M. K. Elbayoumy, A. El-Kattan, A. A. El-Kholy","doi":"10.7774/cevr.2022.11.1.30","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.30","url":null,"abstract":"Purpose The key objective of this study was to formulate a local combined inactivated gel adjuvanted vaccine containing bovine viral diarrhea virus (BVDV)-1, BVDV-2 viruses and Clostridium perfringens type A toxoid. The study evaluated its ability to enhance protective active immune response in camels’ calves against these infectious pathogens under field conditions. Materials and Methods The local BVDV cytopathic strains and a local strain of toxigenic C. perfringens type A were used in vaccines formulation. Vaccines A and B were monovalent vaccines against C. perfringens and both strains of BVDVs, respectively. While the vaccine C was the combined vaccine used against the three agents. All vaccines were adjuvanted with Montanide gel. Sterility, safety, and potency tests were applied on the formulated vaccines. Virus neutralization and toxin anti-toxin neutralization tests were used to evaluate the immune responses. Results Both monovalent (vaccine A) and combined vaccines (vaccine C) showed a protective level (4.5 and 3 IU/mL, respectively) against C. perfringens from the 2nd-week post-vaccination. The titer declined to 3 and 2 IU/mL, respectively at the 5th-month post-vaccination. The titer against BVDV, the monovalent vaccine (vaccine B) reached the beak (1.95 IU/mL) at the 1st-month post-vaccination and lasted till 6th-month post-vaccination (0.92 and 0.94 IU/mL) for BVDV-1a and BVDV-2, respectively. Conclusion Vaccination of camels with the combined vaccine adjuvanted by Montanide gel containing C. perfringens type A toxoid and BVDV strains with 6-month intervals is recommended to protect camels safely and efficiently against such infections in the field.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"30 - 42"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49551602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Knowledge, attitude, and practices regarding human papillomavirus and its’ vaccination among the young medical professionals and students of Bangladesh 孟加拉国年轻医疗专业人员和学生关于人乳头瘤病毒及其疫苗接种的知识、态度和做法

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.63

Sreshtha Chowdhury, R. Ara, Simanta Roy, Syed Md Sayeem Tanvir, Fahima Nasrin Eva, Tasnova Mehrin Neela, Amena Akter Moonmoon, Shamma Sifat, Mushfera Zamila, M. D. Hawlader

{"title":"Knowledge, attitude, and practices regarding human papillomavirus and its’ vaccination among the young medical professionals and students of Bangladesh","authors":"Sreshtha Chowdhury, R. Ara, Simanta Roy, Syed Md Sayeem Tanvir, Fahima Nasrin Eva, Tasnova Mehrin Neela, Amena Akter Moonmoon, Shamma Sifat, Mushfera Zamila, M. D. Hawlader","doi":"10.7774/cevr.2022.11.1.63","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.63","url":null,"abstract":"Purpose Sexually transmitted infections are a major worldwide concern, and human papillomavirus (HPV) is one of the significant risk factors. Many populations suffer from various diseases caused by HPV, and the overall death toll due to cervical carcinoma is remarkable. Despite vaccine availability, perception about vaccine safety and efficacy, its’ preventive outcome is still inferior among the health professionals and vaccine providers. So, this study aims to assess the knowledge, attitude, and practice level of HPV and its’ vaccination among doctors, dentists, and medical students. Materials and Methods This cross-sectional survey was carried out between April to August 2021, where 626 participants from all types of medical institutions of Bangladesh were interviewed using a validated and structured questionnaire that consists of four extensive areas; socio-demographic characteristics, HPV knowledge, attitude, and practices regarding vaccination. Results The knowledge and practice standards showed very poor outcomes where 43.29% of the participants showed good knowledge and only 11.82% conveyed good practices. Nevertheless, the attitude towards HPV vaccination was revealed high (75.88%). Female participants showed more positive attitudes than males. Conclusion Physicians and dentists play vital roles in raising public knowledge about HPV and awareness regarding HPV vaccination programs. The provision of medical education on HPV must be prioritized, and current training techniques must be re-evaluated. Thus, by implementing this strategy, improvement in national vaccination policy can be expected.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"63 - 71"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46870045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults 印度尼西亚成人冠状病毒疫苗抗sars - cov -2受体结合域抗体的评价

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.116

Juandy Jo, Astia Sanjaya, R. Pinontoan, Maroloan Aruan, R. M. Wahyuni, Venansi Viktaria

引用次数: 3

The risk of confusion between AstraZeneka COVID-19 vaccine side effects and signs of COVID-19 infection: a case report 阿斯利康新冠肺炎疫苗副作用与新冠肺炎感染迹象之间混淆的风险：一份病例报告

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.125

M. Nomali, Mahdieh Afzali

{"title":"The risk of confusion between AstraZeneka COVID-19 vaccine side effects and signs of COVID-19 infection: a case report","authors":"M. Nomali, Mahdieh Afzali","doi":"10.7774/cevr.2022.11.1.125","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.125","url":null,"abstract":"Post-vaccination side effects of AstraZeneca (AZ) coronavirus disease 2019 (COVID-19) vaccine are common. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection immediately after the first dose of AZ COVID-19 vaccine has not been reported. In this case, a 30-year-old female without a past medical history of SARS-CoV2 infection presented to an outpatient clinic with lightheadedness and weakness 2 hours after getting the first dose of the AZ COVID-19 vaccine. Blood pressure (BP) was 80/60 mm Hg, and oxygen saturation (SpO2) was 98%. After administering normal saline intravenous fluid, the BP was 110/80 mm Hg. On the first day, fever (oral temperature of 39℃), sweating, dry cough, sore throat, and injection-site pain were presented. On the second day, diarrhea, productive cough, and hypotension occurred in addition to fever (oral temperature of 39.9℃). The fever did not stop and productive cough, change in smell, and fatigue were reported. SpO2 was 96%. On the third day, no abnormality of the spiral lung computed tomography and the positive reverse transcriptase-polymerase chain reaction (RT-PCR) test were reported. Simultaneously, two out of three members of the family became symptomatic on the second day and their RT-PCR tests were positive. Dexamethasone ampule, Cefixime tablet, Acetaminophen tablet, and Diphenhydramine syrup were prescribed. After a week, fever subsided and SpO2 was 98%. After 3 weeks of self-quarantine at home, her general condition improved. Despite the similarity between SARS-CoV2 infection signs and symptoms and AZ COVID-19 vaccine side effects, none of the approved vaccines contain the live virus that causes disease. Therefore, any unusual post-vaccination signs and symptoms should not be attributed to the vaccine itself and need to be considered for further evaluations and early actions in order to prevent the spread of the disease in society.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"125 - 128"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45241744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison and efficacy of two different sheep pox vaccines prepared from the Bakırköy strain against lumpy skin disease in cattle Bakırköy株制备的两种不同羊痘疫苗对牛块状皮肤病的疗效比较

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.1

S. Uzar, F. Sarac, V. Gulyaz, Hakan Enul, H. Yılmaz, N. Turan

{"title":"Comparison and efficacy of two different sheep pox vaccines prepared from the Bakırköy strain against lumpy skin disease in cattle","authors":"S. Uzar, F. Sarac, V. Gulyaz, Hakan Enul, H. Yılmaz, N. Turan","doi":"10.7774/cevr.2022.11.1.1","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.1","url":null,"abstract":"Purpose Lumpy skin disease (LSD) is a highly contagious and economically important viral infection of cattle, which leads to financial losses in the livestock industry of affected countries. Vaccination is the most effective control measure to prevent the disease. Heterologous sheep pox (SP) vaccine was used against LSD in Turkey. In this research, it was aimed to adapt SP Bakırköy vaccine strain attenuated in lamb kidney cells to Madin-Darby bovine kidney (MDBK) cells to provide better protection than commercial SP vaccine in cattle. Materials and Methods To evaluate safety and efficacy of vaccines, while animals were immunized with 10 doses (104.75 50% tissue culture infectious dose [TCID50]) and 5 doses of SP vaccine (104 TCID50) produced in MDBK cells, others were immunized with commercial Penpox-M vaccine (103.9 TCID50). Two cattle were kept as unvaccinated. At day 31 post-vaccination, all animals were challenged with the virulent LSD virus. Blood and swab samples were taken on certain days post-inoculation. Logarithmic differences challenge virus titers between vaccinated and unvaccinated animals were calculated. Results The clinical sign was not observed in animals immunized with 10 doses of SP vaccine. The differences between the animals immunized with SP vaccine and control group was less than log 2.5 and the viremia occurred in immunized animals. The difference in titer was higher than log 2.5 in animals immunized with the Penpox-M, and viremia did not occur. Conclusion SP vaccine strain propagated in MDBK cells and can be used for immunization to prevent LSD infections. However, SP vaccine strain propagated in MDBK showed poor protection as compared to Penpox-M.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"1 - 11"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47133636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

COVID-19 vaccines development in Africa: a review of current situation and existing challenges of vaccine production 非洲COVID-19疫苗开发:对疫苗生产现状和现有挑战的审查

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.82

E. Lamptey, E. Senkyire, Dooshima Aki Benita, E. Boakye

引用次数: 8

Shingles and mRNA COVID-19 vaccine. 带状疱疹和mRNA COVID-19疫苗。

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2021-09-01 Epub Date: 2021-09-30 DOI: 10.7774/cevr.2021.10.3.292

Rujittika Mungmunpuntipantip, Viroj Wiwanitkit

引用次数: 0